1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 234 results for "Multiple Myeloma (MM)".

Thumbnail for Racial and Ethnic Disparities in Radiation Therapy Utilization Among Patients With Multiple Myeloma and Bone Metastasis: A Real-World Analysis Using TriNetX

MM - 1098

Racial and Ethnic Disparities in Radiation Therapy Utilization Among Patients With Multiple Myeloma and Bone Metastasis: A Real-World Analysis Using TriNetX

Juhi Ardeshna-Chovatiya

Poster Presenter: Juhi Ardeshna-Chovatiya

$Thumbnail for Impact of Dose Modifications on Efficacy Outcomes With Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma: Insights From the DREAMM-7 Third-Line or Later Proteasome Inhibitor/Immunomodulatory Agent-Exposed Subgroup$

MM - 1100

Impact of Dose Modifications on Efficacy Outcomes With Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma: Insights From the DREAMM-7 Third-Line or Later Proteasome Inhibitor/Immunomodulatory Agent-Exposed Subgroup

Al-Ola Abdallah

Poster Presenter: Al-Ola Abdallah

SOHO 2026 Annual Meeting

Topics

Racial and Ethnic Disparities in Radiation Therapy Utilization Among Patients With Multiple Myeloma and Bone Metastasis: A Real-World Analysis Using TriNetX

Impact of Dose Modifications on Efficacy Outcomes With Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma: Insights From the DREAMM-7 Third-Line or Later Proteasome Inhibitor/Immunomodulatory Agent-Exposed Subgroup

Mental Health and Malignancy: Real-World Associations Between Early-Onset Multiple Myeloma and Mental Illness

Arlocabtagene Autoleucel in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Final Analysis From the Phase 1 Study

Closing the Gap or Widening the Divide? Racial and Sex Disparities in Multiple Myeloma Mortality in the United States, 1999-2020

CRAB-Related Complication Burden in Multiple Myeloma Hospitalizations: Mortality, Organ Support, and Resource Utilization in the National Inpatient Sample Database

Efficacy Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Baseline Renal Impairment Treated With at Least 2 Prior Lines of Therapy in the DREAMM-7 Trial

Persistent Inequities in Multiple Myeloma Mortality Despite Therapeutic Advances in the United States

Comparative Efficacy of Carfilzomib-Based Versus Bortezomib-Based Regimens in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Trials